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Objectives The primary aim of the study was to determine the antiplatelet effects of prasugrel ver-
sus high-dose clopidogrel in patients with high on-treatment platelet reactivity (HTPR) after percutane-
ous coronary intervention (PCI) and, secondarily, their relation to cytochrome (CYP) 2C19*2 carriage.
Background High on-treatment platelet reactivity after clopidogrel administration after PCI is linked
to the loss-of-function CYP2C19*2 allele and accompanied by an increased risk of adverse events.
Methods We performed a prospective, randomized, single-blind, crossover study of platelet inhibi-
tion by prasugrel 10 mg/day versus high-dose 150 mg/day clopidogrel in 71 (of 210 screened;
33.8%) post-PCI patients with HTPR. Platelet function was assessed by the VerifyNow assay (Accu-
metrics, San Diego, California), and real-time polymerase chain reaction genotyping was performed
for CYP2C19*2 carriage.
Results The primary endpoint of platelet reactivity (measured in platelet reactivity units) at the end
of the 2 treatment periods was lower after prasugrel compared with clopidogrel (least-squares esti-
mates 129.4, 95% conﬁdence interval [CI]: 111.1 to 147.7 versus 201.7, 95% CI: 183.2 to 220.2;
p  0.001). The least-squares mean difference between the 2 treatments was 122.9 (95% CI:
166.7 to 79.2, p  0.001), and 47.5 (95% CI: 79.5 to 15.4, p  0.004), in carriers and non-
arriers of at least 1 mutant allele, respectively. The HTPR rates were lower for prasugrel than for
lopidogrel, in all patients (7.5% vs. 35.8%, p  0.001), in carriers (5.3% vs. 47.4%, p  0.007), and in
oncarriers (8.8% vs. 29.4%, p  0.005), respectively.
onclusions In patients with HTPR after PCI, prasugrel is more effective compared with high clopi-
ogrel in reducing platelet reactivity, particularly in CYP2C19*2 carriers. Genotyping guidance might
e helpful only in case an increased clopidogrel maintenance dose is considered. (Prasugrel Versus
igh Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention
PCI); NCT01109784) (J Am Coll Cardiol Intv 2011;4:403–10) © 2011 by the American College of
ardiology Foundation
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404Dual antiplatelet therapy with aspirin and clopidogrel has
become the cornerstone of the medical regimen for preven-
tion of ischemic events in patients undergoing percutaneous
coronary intervention (PCI) with stent placement. Interin-
dividual variability in platelet response to clopidogrel has
been reported (1), with several mechanisms (intrinsic high
platelet reactivity [PR], variability of the drug metabolism,
and various drug interactions) being implicated for high
See page 411
post-clopidogrel treatment PR. The highly polymorphic
cytochrome (CYP) P450 system of the liver plays a key role
in clopidogrel metabolism, with the loss-of-function allele
CYP2C19*2 being associated with a blunted antiplatelet
response to clopidogrel (2). High on-treatment platelet
reactivity (HTPR) is associated with an increased risk of
adverse events after PCI (3–5), with this risk specifically
linked with the presence of the loss-of-function allele
CYP2C19*2 (6–8).
The boxed warning to the
clopidogrel label recently added
by the U.S. Food and Drug Ad-
ministration emphasized the in-
creased risk of adverse cardiovas-
cular outcomes in persons
harboring the poor metabolizer
genotypes and advocated imple-
menting strategies aimed at ad-
justing clopidogrel dosing or the
use of alternative antiplatelet
agents (9). However, the issue of
whether to perform CYP2C19
testing was left up to the indi-
vidual physician, as pointed out
in the American College of Cardiology Foundation/
American Heart Association clopidogrel clinical alert
(10). Increasing the usual 75 mg/day clopidogrel to 150
mg/day seems to be a reasonable approach to overcome
low responsiveness (11–14). More potent antiplatelet
therapies could be an alternative for patients with HTPR.
Prasugrel, like clopidogrel, binds to and inhibits the
P2Y12 receptor, but because of metabolic differences in
the generation of the active metabolite, this inhibition
occurs more rapidly, consistently, and to a greater extent
than with standard or even high-dose clopidogrel (15–
17). In vitro and in vivo studies of prasugrel indicate
minor contribution of CYP2C9 and CYP2C19 to its
metabolic activation (18). Prasugrel compared with clopi-
dogrel resulted in better clinical outcomes in patients
with acute coronary syndromes with planned PCI, at a
cost of higher rates of TIMI (Thrombolysis In Myocar-
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CI  confidence intervals
CYP  cytochrome
HTPR  high on-treatment
platelet reactivity
LS  least squares
PCI  percutaneous
coronary intervention
PR  platelet reactivity
PRU  platelet reactivity
unit(s)dial Infarction) major bleeding (19).Optimization of post-PCI platelet inhibition in patients
with HTPR is a controversial issue, with little information
available about the use of strategies of more benefit for such
patients. The primary aim of the present study was to
investigate the relative antiplatelet effects of prasugrel versus
high-dose clopidogrel in patients with HTPR after PCI, as
measured by a point-of-care assay. A secondary, hypothesis
generating endpoint was to explore any possible association
of this antiplatelet response to CYP2C19*2 genotyping.
Methods
Study protocol. We performed a prospective, single-center,
single-blinded, investigator-initiated, randomized, cross-
over study to compare platelet inhibition by prasugrel 10
mg/day versus high-dose clopidogrel 150 mg/day in patients
with HTPR after PCI. All consecutive patients undergoing
PCI with stent implantation in our institution were consid-
ered for PR assessment at 24 h after the procedure (or at
48 h in case of IIb/IIIa inhibitors administration). Patients
were excluded if they had a history of bleeding diathesis,
chronic oral anticoagulation treatment, contraindications to
antiplatelet therapy, PCI or coronary artery bypass grafting
(CABG) 3 months, hemodynamic instability, platelet
count 100,000/l, hematocrit 30%, and creatinine
learance 25 ml/min. Patients with a history of stroke
ere excluded from the study as they were considered to
ave contraindication for prasugrel administration. How-
ver, HTPR patients weighing 60 kg, or 75 years of age
were not excluded, as they were considered to be at high
risk for ischemic events. At the time of PCI, clopidogrel
naïve patients and patients receiving clopidogrel 75 mg
for 7 days without an initial loading dose received 600 mg
clopidogrel. Patients receiving clopidogrel 7 days but with
a 300-mg loading dose or patients receiving clopidogrel for
7 days did not receive any additional loading. All patients
received an intra-arterial dose of 100 to 140 U/kg heparin.
Use of periprocedural glycoprotein IIb/IIIa inhibitors was
allowed, at the operator’s discretion. After PCI, all patients
received aspirin 325 mg/day for 1 month and 100 mg/day
thereafter.
Patients with HTPR (as defined in the following text)
were randomized (day 0) in a 1:1 ratio, using computerized
random-number generation by an independent investigator,
to clopidogrel 150 mg a day or prasugrel 10 mg a day until
day 30 after randomization. A day 30  2 visit was
performed for PR measurement and safety evaluation, with
the blood sample being obtained 4 to 6 h after the last study
drug dose. Patient compliance with antiplatelet therapy
was assessed by interview and tablet counting, followed
by crossover directly to the alternate therapy for an
additional 30 days without an intervening washout pe-
riod. At day 60  2, patients returned for the clinical and
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405Physicians and operators who performed platelet function
testing were blinded as to the actual drug used, and an
independent physician monitored bleeding and adverse
event data. A flow chart diagram of the study is shown in
Figure 1.
Platelet function and genotyping assays. Peripheral venous
blood samples were drawn in a fasting state with a loose
tourniquet through a short venous catheter inserted into a
forearm vein. The first 2 to 4 ml of blood was discarded to
avoid spontaneous platelet activation, and blood was col-
lected in 3.2% citrate (1.8 ml–draw plastic Vacuette tubes,
Greiner, Monroe, North Carolina). Platelet-function test-
ing was performed with the VerifyNow (Accumetrics, San
Diego, California) point-of-care P2Y12 assay. An intra-
assay variability of 2.1  1.3% with a 6% coefficient of
variation has been described (4). Results are reported as
P2Y12 reactivity units (PRU), with a value 235 consid-
ered an indication of HTPR (3).
Genotyping was performed for variation in CYP2C19.
Genomic deoxyribonucleic acid was isolated from 2 ml of
ethylenediaminetetraacetic acid–anticoagulated whole
blood from patients, using the QIAamp DNA Blood
Mini Kit (Qiagen, Hilden, Germany). Single nucleotide
Figure 1. Study Flow Chart
PRU  platelet reactivity unit(s).polymorphism CYP2C19*2 (G681A) was detected usingprimers as previously described (20). Genotyping was
performed in the LightCycler2.0 apparatus (Roche,
Mannheim, Germany). Polymerase chain reaction ampli-
fication was carried out using LightCycler capillaries
(Roche), with 50 ng of genomic deoxyribonucleic acid, 0.4
M of each primer, and 0.2 M of each fluorescent probe
nd reaction mixture (QuantiFast Probe PCR, Qiagen) in a
otal reaction volume of 20 l.
Endpoints. Endpoints were pre-specified in the study pro-
ocol and statistical analysis plan. The primary endpoint was
R assessed at the end of the 2 study periods (pre-crossover
nd post-crossover). The HTPR rate during the same
eriods was a secondary endpoint. Bleeding (major, minor,
r minimal according to the TIMI study criteria) and major
dverse cardiac events (cardiovascular death, myocardial
nfarction, and stroke) were evaluated during the pre-
rossover and post-crossover periods.
Statistical analysis. For sample size calculation, we hypoth-
esized that prasugrel 10 mg would result in a PR absolute
difference of 50 PRU compared with clopidogrel 150 mg
(with the assumption that the within-patient standard
deviation of the response variable is 70 PRU), based on
previously published data (17). Choosing a power of 95%
and a 2-sided alpha-level of 0.05, at least 53 patients in total
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406were required to reach statistical significance on the basis of
the preceding assumptions.
Categorical data are presented as frequencies and group
percentages, and continuous data as means  SD. Two-
sample t test and the Fisher exact test were used for
comparison of continuous and categorical data, respectively.
All tests were 2-tailed, and statistical significance was
considered for p values 0.05. Analyses were performed
using SPSS for Windows (version 16.0, SPSS, Chicago,
Illinois). Only patients who successfully completed at least 1
period of the study were considered for analysis. The
primary study endpoint was analyzed by a hierarchical
analysis of covariance (or mixed-effects) model, with patient
indicator as random effect, period and treatment as fixed
factors, and PR at baseline as a covariate. Least squares (LS)
estimates of the mean difference are presented, with 95%
confidence intervals (CI) and a 2-sided p value for the
treatment effect. Separate analyses of covariance were con-
ducted for the before and after crossover period, with
treatment as fixed effect and PR at baseline as a covariate.
To test for period effect, we compared the absolute PR
mean difference between pre-crossover period and post-
crossover period within the 2 treatment sequences, with a
2-sample t test. To test for carry-over effect, we compared
the PR average in pre-crossover period and post-crossover
period between the 2 sequences with a 2-sample t test. The
secondary study endpoint was analyzed with a chi-square
Prescott test for subjects with both day 30 and day 60 data
available. Bleeding events and major adverse cardiac events
are reported in a descriptive manner.
The study was approved by the ethics committee of the
University Hospital of Patras, Greece. All patients gave
written informed consent.
Results
Of 210 patients with PR assessment, 71 (33.8%) were
identified to have HTPR and were randomized. Until day
30, side effects leading to study drug discontinuation oc-
curred in 2 patients, and low compliance was observed in 5
patients, leaving 64 patients available to test the study
hypothesis. Baseline characteristics of patients analyzed are
shown in Table 1. Among patients receiving clopidogrel
followed by prasugrel, age was higher and body mass index
was lower compared with the prasugrel followed by clopi-
dogrel patients. The primary endpoint of PR was signifi-
cantly lower in patients receiving prasugrel (129.4, 95% CI:
111.1 to 147.7) compared with high-dose clopidogrel (201.7,
95% CI: 183.2 to 220.2), with a LS mean difference of
72.3 (95% CI: 98.3 to 46.4, p  0.001). Data for the
pre-crossover and post-crossover periods are shown in
Figure 2. Analysis of PR with body mass index (cut point 30kg/m2) and age (cut point 65 years) as additional fixed
factors showed similar results (LS mean difference, 72.2,
95% CI: 97.9 to 46.5, p  0.001). No period or
carry-over effect was found. The secondary endpoint of
HTPR rate was lower for prasugrel (4 of 53, 7.5%)
compared with clopidogrel (19 of 53, 35.8%, p  0.001).
Individual PR values according to treatment, with the
HTPR threshold, are depicted in Figure 3.
Genotyping revealed carriage of 1 CYP2C19*2 loss-of-
function allele in 35.6% of patients without any homozygote
identified. The PR was significantly lower for prasugrel in
both noncarriers and carriers, with a mean difference be-
tween the 2 treatments of 47.5 PRU (95% CI: 79.5 to
15.4, p  0.004) and 122.9 PRU (95% CI: 166.7 to
79.2, p  0.001) in noncarriers and carriers, respectively.
Data for the pre-crossover and post-crossover periods are
shown in Figure 4. Among carriers, 9 of 19 (47.4%)
continued to demonstrate HTPR despite high clopidogrel
maintenance dose, whereas only 1 of 19 (5.3%) remained
poor responders to prasugrel (p  0.007). Among noncar-




(n  32) p Value
Age, yrs 67.9 10.5 62.2 10.8 0.03
Men 28 (87.5) 29 (90.6) 1.0
BMI, kg/m2 27.9 4.3 30.1 3.9 0.03
Hyperlipidemia 22 (68.8) 19 (59.4) 0.6
Hypertension 22 (68.8) 21 (65.6) 1.0
Diabetes mellitus 13 (40.6) 10 (31.2) 0.6
Smoking 14 (43.8) 16 (50.0) 0.8
Prior myocardial infarction 3 (9.4) 5 (15.6) 0.7
Prior CABG 1 (3.1) 3 (9.4) 0.6
Prior PCI 2 (6.2) 3 (9.4) 1.0
Peripheral arterial disease 1 (3.1) 2 (6.2) 1.0
Statin use 32 (100) 31 (96.9) 1.0
Proton pump inhibitors use 32 (100) 30 (93.8) 0.5
Beta-blocker use 31 (96.9) 28 (87.5) 0.4
Nitrates use 12 (37.5) 8 (25) 0.4
Reason for PCI
Myocardial infarction 16 (50) 14 (43.8) 0.8
Unstable angina 6 (18.8) 9 (28.1) 0.6
Stable angina 0 (0) 2 (6.2) 0.5
Ischemia in provocative test 10 (31.2) 7 (21.9) 0.6
GFR 60 ml/min 6 (18.8) 4 (12.5) 0.7
GP IIb/IIIa inhibitor administration 6 (18.8) 7 (21.9) 1.0
Chronic clopidogrel use, 7 days 6 (18.8) 8 (25.0) 0.8
PRU, day 0 292.0 50.4 289.9 42.9 0.9
One CYP2C19*2 allele [n 29] 9 (31.0) [n 30] 12 (40.0) 0.6
Data are presented as mean SD or n (%).
BMI body mass index; CABG coronary artery bypass grafting; GFR glomerular filtration
rate; GP  glycoprotein; PCI  perutaneous coronary intervention; PRU  platelet reactivity
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407responders to clopidogrel 150 mg and prasugrel (p  0.005),
respectively. A not pre-specified analysis of PR in relation to
CYP2C19*2 carriage separately for each treatment arm
Figure 2. PR by Treatment Sequence
Data for the pre-crossover and post-crossover periods are depicted. Least-
squares estimates and 95% conﬁdence intervals are presented. Black line
indicates clopidogrel; green line indicates prasugrel. PR  platelet reactiv-
ity; PRU  platelet reactivity unit(s).
Figure 3. Individual PR Responses According to Treatment
Data for the pre-crossover and post-crossover periods are depicted. Lines repr
reactivity (PR) in the upper quartile (asterisks) and lower quartiles (open circl
under prasugrel (solid green circles) on day 30 remained in the same quartile
lower quartiles under clopidogrel on day 30 dispersed across all 4 quartiles un
platelet reactivity unit(s).showed that clopidogrel 150 mg resulted in less PR reduc-
tion in carriers, with a mean difference of 38.6 PRU
between noncarriers and carriers (p  0.04). The difference
in PR reduction achieved by prasugrel between noncar-
riers and carriers was not statistically significant (30.8
PRU, p  0.1). Although our study was not designed and
adequately powered for this analysis, HTPR rates in
noncarriers and carriers, separately for each treatment
arm, did not differ significantly (28.6% vs. 50%, p  0.1,
or clopidogrel and 8.1% vs. 5%, p  1.0, for prasugrel,
espectively).
During the pre-crossover period, 1 patient had TIMI
riteria major bleeding and 1 had acute myocardial
nfarction with documented in-stent thrombosis, both
llocated to clopidogrel and both excluded from analysis.
hree patients (allocated to prasugrel) experienced minor
leeding events. During the post-crossover period, 1
atient had TIMI major bleeding and another experi-
nced a minor bleeding event (both allocated to clopi-
ogrel). No deaths or strokes occurred in either treatment
roup. There were no differences between patients finally
nalyzed and patients randomized but discontinued be-
ore day 30.
medians, and error bars represent interquartile range. Patients’ platelet
day 30 are shown. The majority of patients in the upper and lower quartiles
er clopidogrel (solid black circles) on day 60. Patients in the upper and
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408Discussion
This study demonstrates that, among post-PCI patients
with HTPR under usual clopidogrel treatment, prasugrel
compared with high-dose clopidogrel results in higher
platelet inhibition, with fewer patients remaining nonre-
sponsive after prasugrel than after high-dose clopidogrel.
This effect is closely linked to the presence of the allelic
variant of CYP2C19*2. High clopidogrel dose, in contrast
to prasugrel, is frequently ineffective in the presence of
the CYP2C19*2 allele.
Overcoming HTPR. Switching from the usual 75 mg/day
clopidogrel to 150 mg/day overcomes low responsiveness in
a variable proportion of patients (11–14). However, a
suboptimal clopidogrel response was still present in 60% of
diabetic patients in the OPTIMUS (Optimizing Antiplate-
let Therapy in Diabetes Mellitus) study on the 150-mg
regimen (14). In our study, in a population with HTPR,
more than one-third of patients remained hyporesponsive
after 1 month on high clopidogrel dose. The clinical impact
of high clopidogrel maintenance dose in patients with
HTPR 12 to 24 h after PCI was studied in the recently
presented GRAVITAS (Gauging Responsiveness With a
VerifyNow Assay–Impact on Thrombosis and Safety) trial
(21). The primary outcome of cardiovascular death, myo-
cardial infarction, or stent thrombosis occurred in 2.3% of
the high-clopidogrel dose group versus 2.3% of the
standard-dose group (p  0.98). A significantly higher
antiplatelet effect with prasugrel compared with high-dose
clopidogrel has been reported in aspirin-treated patients
with coronary artery disease (15), in stable patients under-
going planned PCI (16), and in acute coronary syndrome
patients (17,22). Although there are no clinical data to
support a “goal” of therapy to convert nonresponders into
Figure 4. PR by Treatment Sequence in Noncarriers and Carriers of CYP2C
Data for the pre- and post-crossover periods are depicted. Least-squares estim
green lines indicate prasugrel. Abbreviations as in Figure 2.responders, the use of prasugrel seems to be an attractive gchoice to overcome HTPR. Changing from clopidogrel to
prasugrel maintenance therapy results in further reductions
in maximal adenosine diphosphate–induced platelet aggre-
gation, early after switching therapies in aspirin-treated
healthy subjects or acute coronary syndrome patients
(23,24). Our results are in the same line of evidence. It
should be emphasized, however, that even with prasugrel,
suboptimal platelet inhibition may occur, as we documented
in 7.5% of our cases.
HTPR and CYP2C19*2 carriage. In the ACCEL-DOUBLE
Accelerated Platelet Inhibition by a Double Dose of
lopidogrel According to Gene Polymorphism) study in-
olving patients receiving clopidogrel 150 mg/day for at
east 1 month, carriage of CYP2C19 variant was related to
ncreased PR and predicted the risk of HTPR (25). A better
latelet inhibition was reported in 9 CYP2C19*2 allele
arriers by increasing the clopidogrel maintenance dose
rom 75 to 150 mg/day, although some of them had little or
o response to the higher dose (26). In a recently published
onrandomized study by Barker et al. (27) of 41 genotyped
atients with HTPR, increasing clopidogrel to 150 mg
esulted in no significant difference between carriers and
oncarriers. They concluded that carriage does not seem to
ave a major influence on dose effect. That study involved
elatively few patients and had a limited statistical power. In
ur study, for 59 genotyped patients, we described a
ignificantly smaller PRU reduction by high (150 mg)
aintenance clopidogrel dose in carriers than in noncarriers.
owever, almost half of the carriers remained hyporespon-
ive, suggesting that a “tailored treatment” (with clopi-
ogrel) may not be the ideal solution for HTPR, at least for
arriers.
In contrast to clopidogrel, common functional CYP
Allele
nd 95% conﬁdence intervals are presented. Black lines indicate clopidogrel;19*2
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409dogrel absorption) do not affect active drug metabolite
levels, inhibition of platelet aggregation, or clinical cardiovas-
cular event rates in patients treated with prasugrel (28–30). In
a series of 7 patients with clinical resistance to clopidogrel
anifesting as stent thrombosis, increasing the dose of
lopidogrel did not override the effect of the CYP2C19*2,
hereas a 10-mg dose increase of prasugrel did, suggesting
hat a strategy of an incremental increase in the clopidogrel
n such patients is both time consuming and minimally
ffective (31). Although known genetic and nongenetic
actors explain only a portion of the majority of variation in
latelet inhibition (32,33), our data suggest a role for
enotyping HTPR patients if high-dose clopidogrel is to be
sed.
Study limitations. As agreement between assays to identify
atients with insufficient inhibition of platelet aggregation
y clopidogrel is low, and the assessment of platelet function
nhibition by clopidogrel is highly test specific, our results
pply only for the method we used. The active metabolite
oncentrations of prasugrel and clopidogrel were not
etermined. Variations of pharmacokinetic and pharma-
odynamic profiles in the early phase after initiation of
lopidogrel with different loading protocols might have
nfluenced the HTPR definition. As PR was assessed
elatively early after glycoprotein IIb/IIIa administration
with abciximab used in only 1 case), some patients with
TPR in the initial cohort may have been misclassified as
esponders. Changing the aspirin dose from 325 mg to 100
g during the study may have influenced the platelet
unction determination. However, because of the crossover
esign of the study, we believe this effect on our results is
inimal. There was no washout period between treatments,
s this could not be performed because of the use of
oronary stents in PCI patients. The duration of treatment
hould have been adequate to remove any influence of the
rior therapy, whereas no carryover effect was observed. The
ain-of-function CYP2C19*17 allele was not tested, as well
as other CYP2C19 loss-of-function alleles. The later, how-
ever, are of limited significance (8). The present study was
not powered to detect clinical safety differences between the
2 treatment groups nor to draw any meaningful conclusions
in this regard.
Clinical implications. High-dose clopidogrel affects CYP2C19*2
arriers and noncarriers with HTPR differentially and is
articularly ineffective in carriers. Testing for CYP2C19
ay have a role in these patients, although its value is
iminished in that a significant proportion of CYP2C19*2
arriers do not have HTPR on clopidogrel therapy, whereas
TPR is present in many patients with wild-type alleles.
urs is the first study to examine the relationship between
rasugrel effectiveness and genotyping in patients with
TPR after PCI. As only a very small percentage of
YP2C19*2 carriers remain nonresponsive to prasugrel,reatment with this agent is an attractive solution. Inssence, our results implicate that prasugrel treatment of
atients with HTPR could bypass the need for genotyp-
ng. Further prospective large-scale studies must deter-
ine: 1) whether the benefits of prasugrel therapy in
lopidogrel nonresponders outweigh any potential risk of
ncreased bleeding; and 2) whether clopidogrel therapy—
ven in high doses—provides ischemic outcomes similar to
hose with prasugrel therapy for patients with the
YP2C19 polymorphism. However, the low positive pre-
ictive accuracies for both platelet function assays (13.3% at
est) and genetic testing for ischemic outcomes, and little or
o predictive accuracies for bleeding events (7,29,34–36),
emain a significant obstacle.
onclusions
For patients with HTPR after standard clopidogrel treatment
after PCI, prasugrel 10 mg/day is more effective than clopi-
dogrel 150 mg/day in reducing PR. This effect is more
prominent in patients carrying 1 loss-of-function CYP2C19*2
allele. Hence, in HTPR patients, genotyping guidance might
be helpful only in case an increased clopidogrel maintenance
dose is considered. Measurement of platelet function in a
post-PCI patient and subsequent treatment with prasugrel—if
found with HTPR—seems to be the most effective strategy to
overcome low responsiveness.
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